button bars forest bayes pooled summary circles
 
DCR

mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)

versus placebo
pembrolizumab alone vs. placebo 1 890 [-127; 1906] /10000
173/278 vs. 72/135

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons